FOOD AND DRUG ADMINISTRATION (FDA) 
Center for Drug Evaluation and Research (CDER) 

Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) Meeting 

FDA White Oak Campus, Building 31, The Great Room (Rm. 1503) 

White Oak Conference Center, Silver Spring, Maryland 

 

 

November 7, 2012 

MEETING ROSTER 

 

 

DESIGNATED FEDERAL OFFICER (Non-Voting)  
 
Paul T. Tran, RPh  
Division of Advisory Committee and Consultant Management  
Office of Executive Programs, CDER, FDA 
 
ENDOCRINOLOGIC AND METABOLIC DRUGS ADVISORY COMMITTEE MEMBERS (Voting) 
                                                                                                  
Erica H. Brittain, PhD 
Mathematical Statistician  
Biostatistics Research Branch 
National Institute of Allergy and Infectious  
Diseases (NIAID) 
National Institutes of Health (NIH) 
Bethesda, Maryland 
 

Ellen W. Seely, MD (via telephone) 
Professor of Medicine 
Harvard Medical School 
Director of Clinical Research 
Endocrinology, Diabetes and Hypertension Division 
Vice Chair for Faculty Development 
Department of Medicine 
Brigham & Women's Hospital 
Boston, Massachusetts 
 
Robert J. Smith, MD 
Professor of Medicine (Endocrinology) 
Alpert Medical School of Brown University 
East Providence, Rhode Island 
 

Ed J. Hendricks, MD 
Medical Director  
Center for Weight Management  
Roseville and Sacramento, California  

 

ENDOCRINOLOGIC AND METABOLIC DRUGS ADVISORY COMMITTEE MEMBER  
(Non-Voting) 
 
Mads F. Rasmussen, MD, PhD 
(Industry Representative) 
Executive Director 
Diabetes - Clinical Development and Research 
Clinical Development, Medical and Regulatory Affairs 
Novo Nordisk Inc.  
Princeton, New Jersey 
 
TEMPORARY MEMBERS (Voting) 
 
Elizabeth Bell-Perkins, MPH  
(Acting Consumer Representative)  
Teaching Assistant/Lecturer  
School of Public Health and Health Science  
University of Massachusetts  
Amherst, Massachusetts 

Louise Pace 
(Patient Representative) 
Plymouth, Massachusetts 

Page 1 of 2 

FOOD AND DRUG ADMINISTRATION (FDA) 
Center for Drug Evaluation and Research (CDER) 

Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) Meeting 

 

 

November 7, 2012 

MEETING ROSTER (cont.) 

 

 
 
TEMPORARY MEMBERS (Voting) 
 
Monica C. Skarulis, MD 
CAPT United States Public Health Service 
Senior Clinical Investigator 
Chief, Clinical Endocrine Section 
Diabetes, Endocrine and Obesity Branch 
National Institute of Diabetes and Digestive and Kidney 
Diseases (NIDDK), NIH 
Bethesda, Maryland 
 
Charles A. Stanley, MD 
Professor of Pediatrics 
University of Pennsylvania Perelman School of Medicine 
Division of Endocrinology 
Childrenâ€™s Hospital of Philadelphia 
Abramson Research Center 
Philadelphia, Pennsylvania 
 
FDA PARTICIPANTS (Non-Voting) 
 
Curtis J. Rosebraugh, MD, MPH 
Director 
Office of Drug Evaluation II (ODE-II)  
Office of New Drugs (OND), CDER, FDA  

Dragos Roman, MD 
Clinical Team Leader 
DMEP, ODE-II, OND, CDER, FDA 
 
J. Todd Sahlrott, PhD 
Team Leader and Deputy Director 
Division of Biometrics 2 
Office of Biostatistics 
Office of Translational Sciences (OTS), CDER, FDA 

 

Doris B. Strader, MD 
Associate Professor of Medicine 
Fletcher Allen Health Care 
The University of Vermont, College of Medicine 
Division of Gastroenterology 
Burlington, Vermont 
 

Abraham Thomas, MD, MPH, FACP 
(Acting Chairperson) 
Division Head, Endocrinology, Diabetes, Bone, and 
Mineral Disorders 
Henry Ford Hospital, Whitehouse Chair of 
Endocrinology 
Detroit, Michigan  
 
  
 
Mary H. Parks, MD 
Director  
Division of Metabolism and Endocrinology Products 
(DMEP), ODE-II, OND, CDER, FDA 
 
Naomi Lowy, MD 
Clinical Reviewer 
DMEP, ODE-II, OND, CDER, FDA 
 
 

Page 2 of 2 

